Harmonet 75 mikrogramov/20 mikrogramov obložene tablete Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

harmonet 75 mikrogramov/20 mikrogramov obložene tablete

pfizer europe ma eeig - etinilestradiol; gestoden - obložena tableta - etinilestradiol 20 µg / 1 tableta  gestoden75 µg / 1 tableta; gestoden 75 µg / 1 tableta - gestoden in etinilestradiol

Zycortal Unia Europejska - słoweński - EMA (European Medicines Agency)

zycortal

dechra regulatory b.v. - desoksikorton pivalat - kortikosteroidi za sistemsko uporabo - psi - za uporabo kot nadomestno zdravljenje za mineralocorticoid pomanjkljivost pri psih s primarno hypoadrenocorticism (addison bolezen).

Credelio Unia Europejska - słoweński - EMA (European Medicines Agency)

credelio

elanco gmbh - lotilaner - ectoparasiticides za sistemsko uporabo, isoxazolines - dogs; cats - za zdravljenje bolh in klopi infestations. bolhe in klopi mora priložiti gostiteljice in začne hranjenje, da bi izpostavljene aktivni snovi,. zdravilo za uporabo v veterinarski medicini se lahko uporablja kot del strategije zdravljenja za nadzor alergijskega dermatitisa bolha (fad). dogsthis zdravila zagotavlja takojšnje in dolgotrajne ubijanje dejavnosti za 1 mesec za bolhe (ctenocephalides felis in c. canis) in klopi (rhipicephalus sanguineus, ixodes ricinus, i. hexagonus in dermacentor reticulatus). catsthis zdravila zagotavlja takojšnje in dolgotrajne ubijanje dejavnosti za 1 mesec pred bolhe (ctenocephalides felis in c. canis) in klopi (ixodes ricinus).

Degarelix Accord Unia Europejska - słoweński - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - prostatične neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Provera 100 mg tablete Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

provera 100 mg tablete

pfizer luxembourg sarl - medroksiprogesteronacetat - tableta - medroksiprogesteronacetat 100 mg / 1 tableta - medroksiprogesteron

Provera 500 mg tablete Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

provera 500 mg tablete

pfizer luxembourg sarl - medroksiprogesteronacetat - tableta - medroksiprogesteronacetat 500 mg / 1 tableta - medroksiprogesteron

Fulvestrant Teva 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi Słowenia - słoweński - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

fulvestrant teva 250 mg raztopina za injiciranje v napolnjeni injekcijski brizgi

teva b.v. - fulvestrant - raztopina za injiciranje v napolnjeni injekcijski brizgi - fulvestrant 250 mg / 1 brizga - fulvestrant

Faslodex Unia Europejska - słoweński - EMA (European Medicines Agency)

faslodex

astrazeneca ab - fulvestrant - neoplazme dojke - endokrini terapije, anti-estrogene - faslodex is indicated , as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:, , not previously treated with endocrine therapy, or, with disease relapse on or after adjuvant antiestrogen therapy, or disease progression on antiestrogen therapy. , , , in combination with palbociclib for the treatment of hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy. v pre - ali perimenopausal ženske, kombinacija zdravljenja z palbociclib je treba v kombinaciji z luteinizirajoči hormon sproščujoči hormon (lhrh) agonist.

Sogroya Unia Europejska - słoweński - EMA (European Medicines Agency)

sogroya

novo nordisk a/s - somapacitan - rast - hipofize in hipotalamični hormoni in analogi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).